Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft Versus Host Disease
NCT06824103Phase 4Recruiting
- Sponsor
- Novartis
- Start
- Sep 2025
- Primary completion
- May 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ruxolitinib in chronic graft-versus-host disease (cGVHD), sponsored by Novartis. Started Sep 2025; status: recruiting.
02
Drugs
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT06824103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06824103.